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ABSTRACT Cryptococcosis is a potentially lethal disease of humans/animals caused
by Cryptococcus neoformans and Cryptococcus gattii. Distinction between the two
species is based on phenotypic and genotypic characteristics. Recently, it was pro-
posed that C. neoformans be divided into two species and C. gattii into ﬁve species
based on a phylogenetic analysis of 115 isolates. While this proposal adds to the
knowledge about the genetic diversity and population structure of cryptococcosis
agents, the published genotypes of 2,606 strains have already revealed more genetic
diversity than is encompassed by seven species. Naming every clade as a separate
species at this juncture will lead to continuing nomenclatural instability. In the ab-
sence of biological differences between clades and no consensus about how DNA
sequence alone can delineate a species, we recommend using “Cryptococcus neofor-
mans species complex” and “C. gattii species complex” as a practical intermediate
step, rather than creating more species. This strategy recognizes genetic diversity
without creating confusion.
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Cryptococcosis is one of the most serious fungal diseases encountered by immuno-compromised patients, particularly those with AIDS, throughout the world. The
disease is caused by two pathogenic members of the genus Cryptococcus, C. neofor-
mans and C. gattii, and claims an estimated 625,000 lives annually, with a global burden
of nearly 1 million cases per year (1, 2). Initially, the two etiologic agents were classiﬁed
as one species but were distinguished by their antigenic diversity; C. neoformans strains
are of serotypes A and D, and C. gattii strains are of serotypes B and C (3–6). The
discovery of two different teleomorphs, one for C. neoformans and the other for C. gattii
(5, 6), ultimately led to the recognition of two species, which was later veriﬁed by
whole-genome sequence data (7).
As the phylogenetic species concept became widely accepted from the late 1990s,
phylogenetic trees constructed on the basis of multilocus sequence typing (MLST) and
other molecular typing techniques, such as ampliﬁed fragment length polymorphism
(AFLP) analysis, showed that both C. neoformans and C. gattii strains were composed of
multiple genetically diverse monophyletic clades totaling 7 to 9 (8–14). Recently, a
proposal was made to designate seven MLST clades identiﬁed among 115 strains of
C. neoformans and C. gattii into new species: C. neoformans into two species and
C. gattii into ﬁve species (14). We believe this proposal to be premature for the following
reasons, to be further expanded upon below. (i) Phylogenetic species designation will
almost certainly change, since a sample of less than 5% of the genotyped strains poorly
represents the true diversity within the species complex. (ii) The use of lineage alone to
designate species without readily identiﬁable phenotypic characteristics that distinguish
the species is highly controversial and raises an unsettled issue of how different genomes
should be used in delineation of a species. (iii) Solely using cladistic (phylogenetic) ap-
proaches for species delineation in cryptococcosis agents is inappropriate since they show
various rates of recombination, clonality, and hybridization within and among lineages. (iv)
Renaming important pathogens requires a consensus within the scientiﬁc community to
prevent confusion in the published literature as well as to avoid confusion in clinical
practice. This consensus has not yet been achieved.
GENETIC DIVERSITY WITHIN THE TWO SPECIES AND THE RECENT PROPOSAL OF
SEVEN SPECIES NAMES
C. gattii strains were once considered a monophyletic clade, but phylogenetic
studies based on a concordance of genealogies using 6 to 11 unlinked loci have
suggested that C. gattii strains are a complex of multiple phenotypically cryptic species
(8–12, 14, 15), which is typical of an evolving population. This complexity is also
displayed by C. neoformans (9, 11, 12, 14, 16). The most commonly used MLST scheme
includes seven concatenated loci: CAP59, GPD1, IGS1, LAC1, PLB1, SOD1, and URA5,
which were recommended by the International Society for Human and Animal Mycol-
ogy (ISHAM) Genotyping Working Group of Cryptococcus neoformans and C. gattii (17).
The total number of monophyletic clades recognized within the C. neoformans/C. gattii
species complex is increasing as more strains collected globally are being included in
phylogenetic analyses (18). The major monophyletic clades for the two species have
most commonly been designated molecular types VNI (AFLP1), VNII (AFLP1A/IB), VNIII
(AFLP3), and VNIV (AFLP2) for C. neoformans and molecular types VGI (AFLP4), VGII
(AFLP6), VGIII (AFLP5), and VGIV (AFLP6) for C. gattii. The recent proposal for naming 7
separate species, excluding diploid/aneuploid hybrids formed between different clades
based on MLST data of 115 isolates, is as follows (Table 1): C. neoformans would be
divided into C. neoformans (serotype A, VNI/AFLP1 and VNII/AFLP1A, AFLP1B,VNB,
formerly C. neoformans var. grubii), C. deneoformans (serotype D, VNIV/AFLP2, formerly
C. neoformans var. neoformans), and a C. neoformans  C. deneoformans hybrid
(formerly VNIII/AFLP3 or AD hybrids). C. gattii would be recognized as ﬁve separate
species, namely, C. gattii (VGI/AFLP4), C. deuterogattii (VGII/AFLP6), C. bacillisporus
(VGIII/AFLP5), C. tetragattii (VGIV/AFLP7), and C. decagattii (VGIV and VGIIIc/AFLP10).
The diploid/aneuploid hybrids between isolates of the C. neoformans and C. gattii
complexes are named a C. deneoformans  C. gattii hybrid (AFLP8), a C. neoformans 
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C. gattii hybrid (AFLP9), and a C. neoformans  C. deuterogattii hybrid (AFLP11). A
diligent search by us failed to ﬁnd a correlation between the new species name and
phenotypic characteristics. Susceptibility to antifungal agents, biochemical markers,
virulence based on experimental animals, or prevalence in patients with distinct
underlying conditions revealed some tendencies but were sufﬁciently varied to be
unreliable for differentiation among species. Matrix-assisted laser desorption ioniza-
tion–time of ﬂight (MALDI-TOF) mass spectrometry was used on 423 isolates which had
been molecularly divided into the proposed species. Using an in-house database,
almost all isolates were identiﬁed to the correct species during at least one of two
duplicate trials using a 1.7 cutoff. However, this low cutoff is usually used for genus and
not for species recognition (19). Only 76.1% of strains were identiﬁed correctly by both
tests using the usual species cutoff of 2.0, which questions the practicality of this
method of species identiﬁcation (14). The pros and cons of adopting the new species
system are noted below.
BENEFITS OF ADOPTING THE NEW SPECIES SYSTEM
Because the taxonomic rank of species occupies a pivotal position in every aspect
of biology, adoption of a cryptococcal species recognition system that is compatible
with the advances in phylogenetic theory is critical. The proposed seven species
designations (excluding the four hybrid clades), if generally accepted, would be an
important step in formally recognizing the complex biodiversity within the etiologic
agents of cryptococcosis. Since clinically relevant biological differences between ge-
netically diverged cryptic species are not always obvious, assigning species names to
each clade might accelerate discovery of genetically deﬁned phenotypic differences.
DISADVANTAGES IN ADOPTING THE NEW CLASSIFICATION SYSTEM AT THIS
JUNCTURE
(i) An insufﬁcient number of isolates was studied. One of the most important
concerns is that the proposed species delineation for the etiologic agents of crypto-
coccosis has resulted from an MLST-based phylogenetic analysis of 115 strains (5% of
MLST-genotyped strains). Furthermore, one of the new species, C. decagattii, was
described based on only two strains that were identical by MLST (14) and that may have
originated from the same patient. Differing algorithms with larger numbers of isolates may
divide clades differently. A recent analysis, which included 2,606 strains, already showed
more genetic diversity than is encompassed by seven species (20). A strict, accepted
phylogenetic species concept deﬁnes a species as a single lineage of ancestor-descendant
populations which maintains its identity from other such lineages and which has its own
evolutionary tendencies and historic fate (21–23). With this deﬁnition, even the smallest
TABLE 1 Recently proposed new names for C. neoformans and C. gattii species
complexesa
Current name Molecular type(s) Proposed name
C. neoformans
Var. grubii VNI/VNII/VNB (AFLP1, AFLP1A,
AFLP1B,VNB)
C. neoformans
Var. neoformans VNIV (AFLP2) C. deneoformans
AD hybrid VNIII (AFLP3) C. neoformans  C. deneoformans hybrid
C. gattii VGI (AFLP4) C. gattii
VGII (AFLP6) C. deuterogattii
VGIII (AFLP5) C. bacillisporus
VGIV (AFLP7) C. tetragattii
VGIV/VGIIIc (AFLP10) C. decagattii
DB hybrid AFLP8 C. deneoformans  C. gattii hybrid
AB hybrid AFLP9 C. neoformans  C. gattii hybrid
AB hybrid AFLP11 C. neoformans  C. deuterogattii hybrid
aSee reference 14.
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diagnosable cluster of individual strains that form a monophyletic group in a phylogenetic
tree can be considered deserving of species recognition (24), and the number of crypto-
coccosis agents with a species status will continue to increase (18). For this reason, the
proposed taxonomy is likely to prove to be unstable.
(ii) More of the genome needs to be represented. Since the 11 loci used for the
MLST-based phylogenetic tree represent only 43% of the cryptococcal chromosomes (6
of 14 chromosomes) (14), the true extent of diversity and recombination events will not
be known until more of the chromosomes are included. For example, whole-genome
sequencing recently identiﬁed hitherto-unmapped levels of genomic diversity and
population genetic structure among clinical and environmental isolates of C. neofor-
mans in Africa (25) and led to the discovery of new lineages. Further, until whole-
genome sequencing was carried out, gene introgression from C. neoformans var. grubii
(VNI) to the Paciﬁc Northwest population of C. gattii (old name) strains was not
recognized (26). This observation was also the case with gene introgression from
C. neoformans var. grubii to C. neoformans var. neoformans (27). Although these ﬁndings
of gene introgression do not change the broad-scale phylogenetic relationships, the
ﬁndings illustrate our poor understanding of genetic exchange between different
clades. We need further genome-wide studies to uncover this basic information about
recombination for delimiting species boundaries.
(iii) Models applied for species delineation may not be appropriate. Delineation
of seven species (Table 1) was based on models derived for sexually reproducing and
freely recombining organisms, such as birds, bats, and certain insects (14). As C. neo-
formans and C. gattiimore typically reproduce clonally, the algorithms used may not be
appropriate and may tend to be biased toward declaring clonal lineages as species.
(iv) Species designations are too complex (i.e., routine identiﬁcation is imprac-
tical). Sequencing 11 loci and constructing a phylogenetic tree would need to be
replaced by simpler techniques for routine use, even in reference laboratories. MALDI-
TOF mass spectrometry was too imprecise, particularly for hybrid species (14). A
universally used molecular method of fungal species identiﬁcation is determination of
the nuclear ribosomal internal transcribed spacer (ITS) sequence (28, 29). However, this
option is not available for the identiﬁcation of seven species due to insufﬁcient ITS
sequence variation among the clades/species within either C. neoformans (old name) or
C. gattii (old name) (14, 30).
(v) Species names are confusing. Signiﬁcant confusion will result from using the
names “gattii” and “neoformans” in two different contexts. Until 2015, the name C. gattii
was used for all the strains of serotypes B and C belonging to the VGI to VGIV molecular
types. The same name in the new system refers only to those belonging to the VGI
molecular type (14). This change will cause a disconnection between new C. gattii
strains and prior clinical information on diagnosis, the progression of disease, and
underlying risk factors of the patients infected with old C. gattii strains. This discon-
nection is of particular concern because considerable work on clinical strains and basic
research on C. gattii was carried out using the Vancouver epidemic reference strain
R265 (VGII), which is now proposed as a strain of C. deuterogattii (14). Strain R265 is
highly virulent but is not as neurotropic as other strains of Cryptococcus (31, 32), and
many features of C. gattii learned from using strain R265 may not be applicable to the
new C. gattii strains. In addition, since new names break apart the former C. gattii
strains, the common properties shared by the cryptic species will be lost. The word
“neoformans” has been used for 2 decades to identify not only a species but also a
variety (C. neoformans var. neoformans). The name “C. neoformans” in the new system
refers only to strains of serotype A and molecular types VNI and VNII/VNB and will cause
considerable confusion in referencing the existing results.
(vi) Names for hybrid and aneuploid strains are not readily accommodated.
There are diploid or aneuploid hybrid strains formed by fusion of the strains into two
different clades, such as serotype AD (VNI/VNIV) hybrids (33, 34) and serotype AB
(VNI/VGI) hybrids (35). The frequency of C. neoformans AD hybrid strains among global
Perspective
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clinical isolates is reported to be 6%, slightly higher than that of the VNIV molecular
type (5%) (11), and it is considerably higher (30%) among European clinical isolates (13).
The new name, “C. neoformans  C. deneoformans species hybrid” instead of “AD
hybrids” or “VNIII” will be impractical to use for the strains with such frequency.
Furthermore, the identiﬁcation of AD hybrids by MALDI-TOF mass spectrometry has
been inconsistent (14), and we also do not know whether the MALDI-TOF protein
proﬁles of AD aneuploid/diploid hybrids are distinguishable from the homoploid
hybrids (34, 36, 37) formed by mating between VNI (new name, C. neoformans) and
VNIV (new name, C. deneoformans) strains. Though recombinant haploids are infre-
quent, recent MLST studies have identiﬁed putative recombinant haploids formed
between VNI strains and VNIV strains among clinical and environmental isolates (38).
The homoploid hybrids formed by mating between serotype A and D strains could not
be named in the new species system. Finally, aneuploid hybrids may have extensive
phenotypic variation, depending on which chromosomes are present in duplicate.
PROPOSED USE OF “C. NEOFORMANS SPECIES COMPLEX” AND “C. GATTII
SPECIES COMPLEX”
“Species complex” in biology usually implies that two or more cryptic species are
hidden under one species name, which makes both Cryptococcus neoformans and C.
gattii typical species complexes. Unlike a “species,” a “complex” has no nomenclatural
status and requires no name change. However, the species complexes are clearly
deﬁned by conventional diagnostic methods that can be validated by molecular data.
The term “species complex” has also served the nomenclatural stability of other fungal
taxa, including Fusarium species complex (39) and Scedosporium species complex (40).
CONCLUSIONS
Considering the high global burden of this potentially fatal infection, names given
to the etiologic agents causing cryptococcosis are of paramount importance for both
the mycological community and the medical community. The proposal to divide the
two cryptococcosis agents into 7 haploid and 4 aneuploid/diploid hybrid species
deserves extensive discussion prior to adoption. Since the seven new species are not
known to be clinically distinguishable, universal adoption of the new system of
nomenclature should be delayed until more-detailed studies employing a larger num-
ber of isolates reveal the clinical and biological relevance of the new species. Adoption
of the proposed nomenclature at this juncture might separate taxonomy from clinical
practice and in doing so inhibit the progress of both ﬁelds. Instead of “species,” “species
complex” would accommodate already-known cryptic species and those that might be
discovered in the future. Molecular types within each species complex can be desig-
nated by their molecular type (VNI/AFLP1, VGI/AFLP4, etc.) whenever necessary. Once
clinical and biological relevance becomes apparent for new species distinctions, both
mycologists and clinicians will beneﬁt by using new names.
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